• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Metabolic syndrome does not impair the response to alfuzosin treatment in men with lower urinary tract symptoms: a double-blind, randomized, placebo-controlled study.代谢综合征并不影响α-受体阻滞剂对下尿路症状男性患者的治疗反应：一项双盲、随机、安慰剂对照研究。
Turk J Urol. 2015 Sep;41(3):125-31. doi: 10.5152/tud.2015.89656.
2
Efficacy of Alfuzosin in Male Patients with Moderate Lower Urinary Tract Symptoms: Is Metabolic Syndrome a Factor Affecting the Outcome?阿夫唑嗪在男性中度下尿路症状患者中的疗效：代谢综合征是影响疗效的因素吗？
Urol J. 2020 Aug 25;17(5):517-521. doi: 10.22037/uj.v16i7.6204.
3
Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive medications.一项多中心、前瞻性、比较性队列研究，评估10毫克阿夫唑嗪对有或无抗高血压药物治疗的、提示良性前列腺增生的下尿路症状男性患者血压的疗效和安全性。
Clin Interv Aging. 2015 Jan 17;10:277-86. doi: 10.2147/CIA.S74102. eCollection 2015.
4
Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.两种α-肾上腺素能受体拮抗剂多沙唑嗪和阿夫唑嗪对良性前列腺增生所致下尿路症状患者的疗效比较
BJU Int. 2004 Apr;93(6):757-62. doi: 10.1111/j.1464-410X.2003.04720.x.
5
Randomized Controlled Trial to Assess the Efficacy of the Combination Therapy of Alfuzosin and Tadalafil in Patients with Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia.评估阿夫唑嗪与他达拉非联合治疗良性前列腺增生所致下尿路症状疗效的随机对照试验
Low Urin Tract Symptoms. 2014 Jan;6(1):35-40. doi: 10.1111/luts.12016. Epub 2013 Apr 3.
6
Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.两种剂量（10毫克和15毫克）的阿夫唑嗪或坦索罗辛（0.4毫克）每日一次治疗有症状的良性前列腺增生的疗效和安全性。
BJU Int. 2005 May;95(7):1006-12. doi: 10.1111/j.1464-410X.2005.05456.x.
7
Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.每日一次服用10毫克阿夫唑嗪可预防良性前列腺增生的整体临床进展，但不能预防急性尿潴留：一项为期2年的安慰剂对照研究结果。
BJU Int. 2006 Apr;97(4):734-41. doi: 10.1111/j.1464-410X.2006.06110.x.
8
Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.每日一次服用10毫克阿夫唑嗪治疗下尿路症状和临床良性前列腺增生的安全性和有效性：三项双盲、安慰剂对照研究的汇总分析
BJU Int. 2003 Aug;92(3):257-61. doi: 10.1046/j.1464-410x.2003.04309.x.
9
Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.度他雄胺联合坦索罗辛或单药治疗良性前列腺增生伴下尿路症状患者后国际前列腺症状评分变化的基线变量影响：CombAT 研究 4 年结果。
BJU Int. 2014 Apr;113(4):623-35. doi: 10.1111/bju.12500. Epub 2014 Jan 9.
10
Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.他达拉非对良性前列腺增生继发的下尿路症状及对同时患有这两种病症的性活跃男性勃起功能障碍的影响：来自四项随机、安慰剂对照他达拉非临床研究的汇总数据分析
J Sex Med. 2013 Aug;10(8):2044-52. doi: 10.1111/jsm.12212. Epub 2013 Jun 19.

引用本文的文献

1
Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis.阿夫唑嗪用于良性前列腺增生和下尿路症状的医学治疗：文献系统评价与叙述性综合分析
Ther Adv Urol. 2021 Apr 12;13:1756287221993283. doi: 10.1177/1756287221993283. eCollection 2021 Jan-Dec.

本文引用的文献

1
Associations of cardiorespiratory fitness, physical activity, and obesity with metabolic syndrome in Hong Kong Chinese midlife women.香港中年中国女性的心肺适能、身体活动及肥胖与代谢综合征的关联
BMC Public Health. 2013 Jun 27;13:614. doi: 10.1186/1471-2458-13-614.
2
The impact of metabolic syndrome on the responsiveness to α1-blocker in men with BPH/LUTS.代谢综合征对 BPH/LUTS 男性对 α1 受体阻滞剂反应性的影响。
Int J Clin Pract. 2013 Apr;67(4):356-62. doi: 10.1111/ijcp.12086. Epub 2013 Feb 14.
3
Metabolic syndrome associated with reduced lower urinary tract symptoms in middle-aged men receiving health checkup.代谢综合征与接受健康检查的中年男性下尿路症状减少有关。
Urology. 2012 Nov;80(5):1093-7. doi: 10.1016/j.urology.2012.08.002.
4
Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study.多沙唑嗪胃肠治疗系统与坦索罗辛治疗前列腺增生症下尿路症状的疗效比较：一项多中心、前瞻性、随机研究。
Int J Clin Pract. 2011 Nov;65(11):1193-9. doi: 10.1111/j.1742-1241.2011.02759.x.
5
Metabolic syndrome and accompanying hyperinsulinemia have favorable effects on lower urinary tract symptoms in a generally healthy screened population.代谢综合征和伴随的高胰岛素血症对一般健康筛查人群的下尿路症状有有利影响。
J Urol. 2011 Jul;186(1):175-9. doi: 10.1016/j.juro.2011.03.025. Epub 2011 May 14.
6
Insulin-resistance and benign prostatic hyperplasia: the connection.胰岛素抵抗与良性前列腺增生：关联。
Eur J Pharmacol. 2010 Sep 1;641(2-3):75-81. doi: 10.1016/j.ejphar.2010.05.042. Epub 2010 Jun 9.
7
Lower urinary tract symptoms, obesity and the metabolic syndrome.下尿路症状、肥胖与代谢综合征。
Curr Opin Urol. 2010 Jan;20(1):7-12. doi: 10.1097/MOU.0b013e3283336f3f.
8
Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey.下尿路症状与代谢综合征的关联：波士顿地区社区健康调查结果
J Urol. 2009 Aug;182(2):616-24; discussion 624-5. doi: 10.1016/j.juro.2009.04.025. Epub 2009 Jun 18.
9
Are lower urinary tract symptoms influenced by metabolic syndrome?下尿路症状是否受代谢综合征影响？
Urology. 2009 Mar;73(3):544-8. doi: 10.1016/j.urology.2008.10.027. Epub 2009 Jan 1.
10
Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily.老年良性前列腺增生男性的药物治疗选择：聚焦于阿夫唑嗪每日一次10毫克
Clin Interv Aging. 2008;3(3):511-24. doi: 10.2147/cia.s3635.

代谢综合征并不影响α-受体阻滞剂对下尿路症状男性患者的治疗反应：一项双盲、随机、安慰剂对照研究。

Metabolic syndrome does not impair the response to alfuzosin treatment in men with lower urinary tract symptoms: a double-blind, randomized, placebo-controlled study.

作者信息

Altın Selçuk, Ozan Tunç, İlhan Selçuk, İlhan Nevin, Onur Rahmi

机构信息

Department of Urology, Fırat University Faculty of Medicine, Elazığ, Turkey.

Department of Pharmacology, Fırat University Faculty of Medicine, Elazığ, Turkey.

出版信息

Turk J Urol. 2015 Sep;41(3):125-31. doi: 10.5152/tud.2015.89656.

DOI:10.5152/tud.2015.89656
PMID:26516595
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4608450/
Abstract

OBJECTIVE

This study is a placebo-controlled comparison of the response to alfuzosin treatment for lower urinary tract symptoms (LUTS) in patients with and without metabolic syndrome (MetS).

MATERIAL AND METHODS

A total of 80 men with LUTS were included in the study. Patients had a maximum flow rate of <15 mL/sec, prostate volume of >20 mL, and International Prostate Symptom Score (IPSS) of >8. All eligible men (n=68) for evaluation were initially divided into two groups as MetS (n=34) and non-MetS (n=34) groups. Patients were further randomized to receive alfuzosin (10 mg/day) or placebo (n=17/group; a total of four groups). The outcome was measured at 12(th) week according to the changes from baseline in IPSS, quality of life (QoL) scores, maximum flow rate (Qmax), and postmictional residue.

RESULTS

Alfuzosin significantly improved LUTS in men with and without MetS compared with patients receiving placebo (p<0.05). Mean IPSS scores in treatment groups decreased significantly, whereas patients receiving placebo had no statistically significant difference (p>0.05). Similarly, alfuzosin treatment resulted in a significant increase in Qmax in patients with LUTS/benign prostatic enlargement when compared with patients in placebo group (p<0.05). Mean QoL scores measured by IPSS-QoL and QoL questionnaires also improved significantly in patients receiving alfuzosin for 3 months regardless of the presence of MetS (p<0.05).

CONCLUSION

Our results revealed that the presence of MetS in patients with LUTS did not impair the response to alfuzosin treatment.

摘要

目的

本研究是一项安慰剂对照试验，比较有无代谢综合征（MetS）的患者接受阿夫唑嗪治疗下尿路症状（LUTS）的反应。

材料与方法

共有80名LUTS男性患者纳入本研究。患者的最大尿流率<15 mL/秒，前列腺体积>20 mL，国际前列腺症状评分（IPSS）>8。所有符合评估条件的男性（n = 68）最初被分为MetS组（n = 34）和非MetS组（n = 34）。患者进一步随机分为接受阿夫唑嗪（10毫克/天）或安慰剂治疗（每组n = 17；共四组）。在第12周时，根据IPSS、生活质量（QoL）评分、最大尿流率（Qmax）和排尿后残余尿量相对于基线的变化来测量结果。

结果

与接受安慰剂的患者相比，阿夫唑嗪显著改善了有或无MetS的男性患者的LUTS（p<0.05）。治疗组的平均IPSS评分显著降低，而接受安慰剂的患者则无统计学显著差异（p>0.05）。同样，与安慰剂组患者相比，阿夫唑嗪治疗使LUTS/良性前列腺增生患者的Qmax显著增加（p<0.05）。无论是否存在MetS，接受阿夫唑嗪治疗3个月的患者通过IPSS-QoL和QoL问卷测量的平均QoL评分也显著改善（p<0.05）。

结论

我们的结果显示，LUTS患者中MetS的存在并不影响对阿夫唑嗪治疗的反应。